
Recce Pharmaceuticals Ltd
ASX:RCE

Operating Margin
Recce Pharmaceuticals Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
AU |
![]() |
Recce Pharmaceuticals Ltd
ASX:RCE
|
103.8m AUD |
-169%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
735.9B USD |
40%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404B USD |
26%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
45%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
202.1B CHF |
33%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
178.4B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.5B GBP |
24%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
205.3B USD |
34%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
142.9B USD |
27%
|
Recce Pharmaceuticals Ltd
Glance View
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Recce Pharmaceuticals Ltd's most recent financial statements, the company has Operating Margin of -168.9%.